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Traditionally, vaccines directly target a pathogen or
microbial toxin. Lyme disease, caused by Borrelia
burgdorferi, is a tick-borne illness for which a human
vaccine is not currently available. B. burgdorferi
binds a tick salivary protein, Salp15, during transmis-
sion from the vector, and this interaction facilitates
infection of mice. We now show that Salp15
antiserum significantly protected mice from B. burg-
dorferi infection. Salp15 antiserum also markedly
enhanced the protective capacity of antibodies
against B. burgdorferi antigens, such as OspA or
OspC. Mice actively immunized with Salp15 were
also significantly protected from tick-borne Borrelia.
In vitro assays showed that Salp15 antiserum
increased the clearance of Salp15-coated B. burg-
dorferi by phagocytes, suggesting a mechanism of
action. Vaccination with a vector molecule that
a microbe requires for infection of the mammalian
host suggests a new strategy for the prevention of
Lyme disease, and this paradigm may be applicable
to numerous arthropod-borne pathogens of medical
importance.
INTRODUCTION
Ixodes scapularis ticks can transmit diverse infectious agents,
including Borrelia burgdorferi, Anaplasma phagocytophilum,
and Babesia microti (de la Fuente et al., 2008). Lyme disease,
caused by B. burgdorferi sensu lato, is the most common tick-
borne illness in the United States and selected regions of Eurasia
(Fikrig and Narasimhan, 2006). While taking a blood meal, ticks
attach to their vertebrate host for several days and introduce
saliva, together with pathogens, into the skin. Tick saliva
contains a wide range of physiologically active molecules that
are critical for effective attachment and engorgement (Hovius
et al., 2008a).
Human vaccines against Lyme disease are not currently avail-
able (Nardelli et al., 2009). Several B. burgdorferi outer surface
proteins (Osps) that elicit protective responses, including482 Cell Host & Microbe 6, 482–492, November 19, 2009 ª2009 ElsOspA, OspB, and OspC, among others, have been identified
(Earnhart et al., 2007; Feng et al., 1998; Fikrig et al., 1997; Steere
et al., 1998). OspA has been extensively studied, proven to elicit
varying degrees of immunity in diverse animal models of Lyme
borreliosis, and demonstrated 79% efficacy in phase III human
trials, resulting in an FDA-approved vaccine that was available
from1998 until 2002 (Abbott, 2006). To date, no other spirochetal
antigen has been tested in phase III clinical trials (Earnhart et al.,
2007; Feng et al., 1998; Fikrig et al., 1997).
Infection with B. burgdorferi and potentially other tick-borne
pathogens can also theoretically be prevented by interfering
with the ability of ticks to feed on amammalian host (de la Fuente
et al., 2007b). Repeated exposure of guinea pigs to ticks results
in acquired resistance of the animals to subsequent tick bites,
so-called ‘‘tick-immunity,’’ and can influence tick-transmitted
B. burgdorferi infection (Narasimhan et al., 2007a). Recently,
immunization of guinea pigs with a tick salivary antigen, sialosta-
tin L2, diminished the capacity of I. scapularis nymphs to feed,
thereby identifying one of the antigens that contributes to a
protective response (Kotsyfakis et al., 2008). Vaccines based
on tick gut antigens have also proven partially successful in com-
bating Boophilus tick engorgement on cattle (Kocan et al., 2007).
We nowpropose a new type of vaccine, targeting an arthropod
protein that a pathogen requires for effective transmission to the
mammalian host (Ramamoorthi et al., 2005). The presence of
B. burgdorferi within I. scapularis upregulates the expression of
Salp15, a tick salivary protein. Salp15 is normally used by I. scap-
ularis to inhibit the activation of CD4+ T cells (Anguita et al., 2002),
among other functions, presumably to enhance successful
engorgement on the host. Remarkably,B. burgdorferi coats itself
with Salp15 via a direct interaction with OspC, and this facilitates
spirochete survival in the mammalian host (Ramamoorthi et al.,
2005). We now determine whether immunization with a tick
protein that a pathogen requires for effective transmission to
mice can be used to prevent infection in the mammalian host,
using the Lyme disease agent and Salp15 as the paradigm.
RESULTS
Salp15AntiserumThwarts InfectionwithSalp15-Coated
B. burgdorferi
As Salp15 binds to the surface of B. burgdorferi, we determined
whether Salp15 antibodies could protect mice from infectionevier Inc.
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Salp15 Antiserum Prevents B. burgdorferi InfectionFigure 1. Salp15 Antiserum Diminishes Murine Infection with Salp15-Coated B. burgdorferi
(A–C) The B. burgdorferi load in different tissues was determined by Q-PCR, measuring the spirochete flaB gene copies, and normalized using the murine b-actin
gene. Spirochete burdens in skin (A) at day 7 and in heart (B) and joints (C) at day 21 are shown. Horizontal lines represent the mean values (*p < 0.05 and
**p < 0.01). A representative experiment of three performed is depicted.withSalp15-coated spirochetes.Groupsof tenmicewereadmin-
istered 200 ml of Salp15 antiserum or control antiserum. One day
later, the animalswere challengedwith an intradermal inoculation
of 103 or 104 Salp15-coatedB. burgdorferi, increasing doses that
readily cause infection. At 1 week, the B. burgdorferi burden in
the skin was markedly decreased in mice administered Salp15
antiserum compared with controls (Figure 1A), and 50% of the
mice were fully protected from infection when challenged with
103 Salp15-coated B. burgdorferi. At 3 weeks, when spirochetes
have disseminated to diverse organs, the pathogen burden in the
heart and joints was also significantly lower in mice given Salp15
antiserum (Figures 1B and 1C), and 40% of the mice were fully
protected from infection with a dose of 103 Salp15-coated spiro-
chetes. These studies with an artificial challenge model promp-
ted us to examine the influence of Salp15 antiserum on naturally
tick-transmitted B. burgdorferi infection.
Salp15 Antiserum Enhances the Protective Capacity
of OspA Antibody in a Model of Tick-Transmitted
B. burgdorferi Infection
Immunization with selected B. burgdorferi Osps can provide
substantial, but not necessarily complete, protection against
spirochete infection (de Silva et al., 1999). Our previous study
in mice showed that a titer of at least 6.0 mg of OspA monoclonal
antibody (mAb) C3.78/ml blood was required to protect animals
from tick-transmitted B. burgdorferi (de Silva et al., 1999). We
therefore determined whether Salp15 antiserum would enhance
the protective capacity of this OspA mAb.
Groups of five mice were passively immunized with a low dose
of OspA mAb (4 mg/ml of murine blood), 4 mg/ml of OspA mAbCell Host &plus 100 ml of Salp15 antiserum, a high dose of OspA mAb
(25 mg/ml of mouse blood), 200 ml of Salp15 antiserum, or normal
rabbit serum (control), respectively. One day later, ten B. burg-
dorferi-infected ticks were placed on each mouse, and the path-
ogen burden in themurine skin, heart, and joints was determined
at 3 weeks. First, Salp15 antiserum alone provided significant
protection in the tick-transmission model. Only 55% of the
mice administered Salp15 antiserum hadB. burgdorferi infection
compared with 100% of the control animals (Figure 2A, Table 1).
The B. burgdorferi load was also markedly reduced in the immu-
nized mice, compared with controls and the incidence and
severity of arthritis in animals administered Salp15 antiserum
were decreased (Figures 2A–2C, Table 1). Salp15 antiserum
did not influence tick feeding (the tick engorgement weight
was 4.0 ± 0.2 mg, control versus 4.0 ± 0.2 mg, anti-Salp15), sug-
gesting that this protection was not due to an alteration in the
ability of ticks to take a bloodmeal. The effect of Salp15 antibody
was specific for B. burgdorferi, as experiments with A. phagocy-
tophilum-infected ticks showed that Salp15 antiserum did not
protect mice from challenge with this pathogen (Figure S1).
Salp15 antiserum also enhanced the protective capacity of
a low dose of OspA antibody. Only 25% of the mice treated
with Salp15/OspA antiserum were infected compared with
90% of the animals treated with a low dose of OspA antibody
alone or 100% of the control mice. The spirochete burden in
the combined antibody-immunized groupwas significantly lower
than other experimental or control groups. The degree of protec-
tion was comparable to the group administered the high dose of
OspA mAb alone (Figure 2A, Table 1). In addition, only 20% of
animals given Salp15/OspA antiserum had arthritis comparedMicrobe 6, 482–492, November 19, 2009 ª2009 Elsevier Inc. 483
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Salp15 Antiserum Prevents B. burgdorferi InfectionTable 1. Salp15 AntiserumEnhances theProtective Capacity of OspAAntibody in aModel of Tick-TransmittedB. burgdorferi Infection
Immunogen
Challenge
(no. of Borrelia-
infected nymphs)
No. of tissue specimens
with flaB PCR-positive/No.
of total mice analyzed
flaB copy (normalized by
mouse b-actin) (mean ±SEM)a
No. of arthritis-
positive/No.
of total mice
analyzed
Arthritis
index
(mean ±SEM)bSkin Heart Joint Skin Heart Joint
Normal rabbit
serum
10 19/20 20/20 20/20 79.5 ± 14.9 1123 ± 142.5 961.2 ± 146.9 10/10 2.0 ± 1.0
Low dose
of OspA Ab +
Salp15 Ab
10 4/20 5/20 5/20 3.6 ± 1.7** 41.4 ± 17.3** 64.9 ± 33.0** 2/10 0.5 ± 0.5**
Low dose
of OspA Ab
10 15/20 17/20 18/20 47.1 ± 10.0 690.0 ± 133.8 586.1 ± 147.3 9/10 1.75 ± 1.0
High dose
of OspA Ab
10 0/20 1/20 1/20 0.0 ± 0.0** 1.0 ± 1.0** 1.1 ± 1.1** 1/10 0.25 ± 0.25**
Salp15 Ab 10 11/20 11/20 11/20 27.3 ± 7.1* 332.5 ± 93.7* 290.4 ± 80.4* 6/10 1.0 ± 1.0*
aResults are means +SEM from three Q-PCR experiments. *p < 0.05 and **p < 0.01, when compared with normal rabbit serum control group.
b The knee and tibiotarsal joints were scored for arthritis severity on a scale of 0 (negative) to 3 (severe) in a blinded fashion. *p < 0.05 and **p < 0.01,
when compared with normal rabbit serum control group.with 100% of the control mice, and the degree of inflammation
was very mild compared with control animals, further demon-
strating the ability of antibodies against this tick protein to influ-
ence the course of murine B. burgdorferi infection (Figures 2B
and 2C, Table 1).
As expected, the OspA mAb reduced the B. burgdorferi
burden in I. scapularis after the ticks digested the blood meal,
and this effect was most prominent in the high-dose group. In
contrast, Salp15 antiserum had no effect on the spirochete
burden in ticks either when given alone or in conjunction with
low-dose OspA antibody, further demonstrating that these anti-
bodies predominantly influence B. burgdorferi in the mammalian
host (Figure 2D).
Since Salp15 facilitates spirochete survival during the early
phase of transmission, we postulated that Salp15 antiserum
may influence B. burgdorferi levels at this stage. A detailed anal-
ysis of the spirochete burden at the initial tick bite site showed
that the pathogen load in the localized skin specimen was
most markedly decreased in the combined antibody-immunized
group (Figures 2E and 2F). At day 3, only 40% of mice given
Salp15 antiserum alone and 10% of mice given Salp15/OspA
antiserum were PCR-positive compared with 100% of the
control mice. At day 7, 60% of mice with Salp15 antiserum alone
and 30% of mice with Salp15/OspA antiserum were PCR-
positive compared with 100% of the control animals, and
those infected had markedly reduced levels of B. burgdorferiCell Hoscompared with controls (Figures 2E and 2F). These data suggest
that Salp15 antiserum interfered with spirochete survival at the
early stage of infection.
Salp15 Antiserum Improves the Protective Capacity
of B. burgdorferi OspC Antiserum
In order to assess whether Salp15 antiserum could also enhance
the protective capacity of another B. burgdorferi antigen, we
used OspC antibody in our tick-transmission studies. As
Salp15 binds to OspC during B. burgdorferi transmission and
protects B. burgdorferi from antibody-mediated killing (Rama-
moorthi et al., 2005), we postulated that Salp15 antiserum may
alter the protective effect of OspC antiserum. As previously
reported, OspC antibody partially protected mice against tick-
transmitted B. burgdorferi infection (Probert et al., 1997). We
administered both OspC (two different doses) and Salp15 anti-
serum to mice before tick challenge and demonstrated that
Salp15 antiserum enhanced the protective capacity of OspC
antibody (Figure 3). The spirochete burden in the group adminis-
tered both antisera was significantly lower than other experi-
mental or control groups, both at an early (in the skin at day 7)
(Figure 3A) and at a later (in heart and joints at 21 days) stage
of infection (Figures 3B and 3C). Only 2 of 10 mice treated with
Salp15/high dose of OspC antiserum were infected, compared
with 8 of 10 mice given a high dose of OspC antiserum alone
or 10 of 10 control mice given normal rabbit serum.Figure 2. Salp15 Antiserum Enhances the Protective Capacity of OspA Antibody
(A) Spirochete burden in murine skin, heart, and joints at day 21 after tick feeding.
(B) Arthritis index of the murine joints at day 21 after tick feeding. Horizontal lines represent the mean values of the spots. Results are pooled from at least three
independent experiments.
(C) Histopathology of tarsal joints from mice infected with B. burgdorferi treated with different antibodies. Shown are representative H&E-stained sections from
naive control (no infection) (a, score of 0), normal rabbit serum control (b, score of 2.5), low dose of OspA Ab + Salp15 Ab (c, score of 0.5), low dose of OspA Ab
(d, score of 2.5), high dose of OspA Ab (e, score of 0), and Salp15 Ab (f, score of 1). Tarsal joints frommice treated with a low dose of OspA Ab + Salp15 Ab (c) and
high dose of OspA Ab (e) had the lowest average inflammation scores (scale bars = 1000 mm). Arrows show the leukocyte infiltration and exudation of fibrin and
leukocytes into the joint lumen.
(D) Spirochete burden in ticks at day 7 after tick feeding. (Values represent the mean +SEM of three independent experiments.)
(E) Spirochete burden in mouse skin at day 3 after tick feeding.
(F) Spirochete burden in skin at day 7 after tick feeding. Horizontal lines represent themean values of the spots. Results are pooled from three independent exper-
iments. *p < 0.05 and **p < 0.01, when compared with the normal rabbit serum control group.t & Microbe 6, 482–492, November 19, 2009 ª2009 Elsevier Inc. 485
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Salp15 Antiserum Prevents B. burgdorferi InfectionFigure 3. Salp15 Antibody Enhances the Protective Capacity of OspC Antibody
(A) Spirochete burden in murine skin at day 7 after tick feeding.
(B and C) Spirochete burden in the heart (B) and joints (C) at day 21 after tick feeding. Horizontal lines represent the mean values of the spots. *p < 0.05 and
**p < 0.01, when compared with the normal rabbit serum control group. Results are pooled from three independent experiments.Borrelia Transmission Is Impaired in Mice Actively
Immunized with Salp15
Our passive immunization study showed that Salp15 antiserum
protects mice from tick-transmitted B. burgdorferi infection.
We therefore tested whether mice actively immunized with
Salp15 were also less susceptible to B. burgdorferi infection.
A group of five mice was immunized with recombinant Salp15,
Salp25D (another protein in tick saliva) (Narasimhan et al.,
2007b), or adjuvant alone (mock control). Additionally, 1 day prior
to tick challenge, groups of five Salp15-immunized mice and
five mock mice received a low dose of OspA mAb (4 mg/ml
mouse blood). First, mice generated antibodies against Salp15
following active immunization (Figure 4A); second, after tick
challenge, Salp15-immunized mice were partially protected
against B. burgdorferi infection. At 3 weeks, 40% of Salp15-
immunized mice were fully protected (based on absence of
a detectable flaB signal in quantitative PCR [Q-PCR]), while486 Cell Host & Microbe 6, 482–492, November 19, 2009 ª2009 Els95%–100% of the control animals were infected (Figures 4B–
4D). The mean B. burgdorferi load was also markedly reduced
in Salp15-immunized mice that are positive compared with
controls. Salp15-immunized mice receiving a low dose of
OspA mAb show the best protection rates (80% of mice were
not infected with B. burgdorferi) (Figures 4B–4D). Arthritis was
not visually observed in the mice actively immunized with
Salp15 and then challenged withB. burgdorferi (data not shown).
These data demonstrate that active immunization of mice with
Salp15 prevents tick-transmitted B. burgdorferi infection.
To examine whether active immunization with Salp15 dimin-
ishes antibody production against a pathogen-specific antigen
such as OspA, mice were immunized with OspA, OspA plus
Salp15, or OspA plus Salp25D. Two weeks after immunization,
mice were bled, and the IgG titers of OspA were measured by
ELISA. The OspA antibody titers were comparable among the
three groups (Figure 4E). This suggests that Salp15 can beevier Inc.
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Salp15 Antiserum Prevents B. burgdorferi InfectionFigure 4. Salp15 Active Immunization Provides Mice Protection against Borrelia Infection
(A) Salp15 probed with sera from mice or rabbits actively immunized with Salp15.
(B) Spirochete burden in murine skin at day 7 after tick feeding.
(C and D) Spirochete burden in the heart (C) and joints (D) at day 21 after tick feeding (horizontal lines represent the mean values).
(E) Salp15 did not influence anti-OspA IgG levels at day 14 after immunization (values represent the mean +SEM of three independent experiments).
(F) Spirochete burden in murine skin at day 7 after tick feeding.
(G and H) Spirochete burden in the heart (G) and joints (H) at day 21 after tick feeding. Horizontal lines represent the mean values (*p < 0.05 and **p < 0.01). Repre-
sentative results from at least three independent experiments were shown.administered in conjunction with another antigen that elicits
protective immunity, such as OspA, and will not influence the
antibody production against pathogen-specific antigens.
An initial immunization with OspA followed by several boosts is
required to generate maximal protection against B. burgdorferi
(Fikrig et al., 1990, 1992). We therefore determined whether
active immunization with Salp15 could enhance the protective
capacity of a single immunization with OspA. The results showed
that 70% of the mice immunized with OspA plus Salp15 were
protected, while only about 10%–20% of the mice immunized
with OspA alone or OspA/Salp25D were PCR-negative (Figures
4F–4H). These data suggest that active immunization with
Salp15 can be used to complement the protective effect of
a B. burgdorferi-specific antigen.
Salp15 Antiserum Enhances the Recognition
and Phagocytosis of Spirochetes by Macrophages
To assess the mechanism by which Salp15 antiserum controls
B. burgdorferi infection, we examined the interaction between
spirochetes, Salp15, and Salp15 antiserum. An in vitro binding
assay using overlapping Salp15 peptides suggested that
Salp15 peptides P11 (amino acids 95–114) and P4 (amino acids
31–50) are required for the Salp15-OspC interaction (Figures 5A
and 5B). As Salp15 antiserum recognizes numerous epitopes on
Salp15, including a dominant response to P11 (Figure 5C), the
antibodies are likely to interact with Salp15 that has bound to
OspC on the surface of B. burgdorferi and thereby enhance
clearance by phagocytes. We then assessed whether Salp15
antiserum augments the recognition and phagocytosis of
Salp15-coated spirochetes by macrophages. Confocal micros-Cell Hostcopy showed that cells treated with Salp15 IgG could more
readily identify and digest B. burgdorferi that express GFP
(GFP-B. burgdorferi) (Eggers et al., 2002) than cells treated
with control IgG (Figure 5D). The GFP-B. burgdorferi specifically
colocalized with anti-Salp15 IgG (Figure 5D). FACS analysis
using GFP-producing spirochetes showed that the Salp15 IgG-
treated cells had a higher GFP intensity than control IgG-treated
cells (Figure 5E), indicating that Salp15 IgG recognized the
Salp15 that bound to OspC on the surface of B. burgdorferi,
and these complexes were identified by host cells and opson-
ized. To further confirm that the pathogens were intracellular,
a detail immunostaining was performed. Cells were stained
with OspA antibody prior to fixing and permeabilization so that
spirochetes outside the cells were detected as red. At the
same time, the GFP signal represents spirochetes both inside
and outside the cells (Figure S2).
Salp15 Antibodies Facilitate Phagocytosis of Diverse
Borrelia Species by BoneMarrow-DerivedMacrophages
To examinewhether Salp15 antiserum affords protection against
other Borrelia species, we first tested whether Salp15 is able to
bind to OspC from other Borrelia species. The overlay assay
suggests that Salp15 not only binds to OspC from several
B. burgdorferi sensu stricto isolates (N40, B31, and 297) and
also from Borrelia garinii and Borrelia afzelii, two species that
contribute to Lyme borreliosis in Eurasia (Figure 6A). In an
in vitro phagocytosis assay, we found that Salp15 antiserum
enhanced the phagocytosis of different species of Salp15-
coated Borrelia by bone marrow-derived macrophages
(BMDMs) (Figure 6B). These data suggest that Salp15 may be& Microbe 6, 482–492, November 19, 2009 ª2009 Elsevier Inc. 487
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Salp15 Antiserum Prevents B. burgdorferi InfectionFigure 5. Salp15 Antibody Enhances the Phagocytosis of Spirochetes by Immune Cells
(A and B) Salp15 peptides bind to OspC. Representative results for a binding assay (A) and a competition assay (B) were shown.
(C) Salp15 peptides bind Salp15 antibodies. (Results are means +SEM of three independent experiments. *p < 0.05.)
(D) Confocal image of phagocytosis and spirochete-antibody colocalization (magnification363). Rabbit IgG was stained with TRITC (red); GFP spirochetes were
represented by green. Upper: cells were treated with anti-Salp15 IgG; lower: cells were treated with control rabbit IgG.
(E) FACS analysis of the phagocytic efficiency of the cells and histogram of GFP signal inside the cells (red, no spirochetes; blue, control IgG-treated cells; green,
Salp15 IgG-treated cells). Representative results from at least three independent experiments are shown.488 Cell Host & Microbe 6, 482–492, November 19, 2009 ª2009 Elsevier Inc.
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Salp15 Antiserum Prevents B. burgdorferi InfectionFigure 6. Salp15 Antibodies Enhance Phagocytosis of Different Borrelia Species
(A) Overlay assay with Salp15 and Borrelia lysates. Upper panel: Borrelia lysates overlaid with Salp15 (with V5 tag) and detected by anti-V5 antibodies; middle
panel: Borrelia lysates probed with anti-OspC antibodies; lower panel: Coomassie staining control. Arrows show the position of OspA and OspC.
(B) Confocal image of phagocytosis and spirochete-antibody colocalization (magnification325). Rabbit IgG was stained with TRITC (red); spirochetes were rep-
resented by green (anti-OspA Alexa 488). Nuclei were stained with TOPRO3 (blue). Arrows show the localization of rabbit IgG and spirochetes and the phago-
cytosis of spirochetes.broadly effective as vaccine candidates against diverse B. burg-
dorferi sensu lato species.
DISCUSSION
Vaccines generally target the pathogen directly using extracts of
the organism or recombinant antigens as the immunogen: the
influenza and hepatitis B vaccines are examples. A few vaccines,
such as tetanus toxoid, are aimed at microbial toxins. Another
tactic, applicable to arthropod-borne agents, is immunization
to alter vector engorgement or the inflammation at the feeding
sites and thereby indirectly prevent an infection (Allen and
Humphreys, 1979; de la Fuente et al., 2007a; Labuda et al.,
2006; Narasimhan et al., 2007a). In this study, we propose a
new approach for vaccine development: targeting an arthropod
protein that a pathogen requires for effective transmission to the
mammalian host. Interfering with this interactionmay impede the
ability of a microbe to colonize the vertebrate host in a manner
that is independent of any effect on vector engorgement and
may be used independently or in conjunction with traditional
pathogen-based vaccines.Cell HostSalp15 is a tick protein that facilitates B. burgdorferi infection
of themammalian host (Ramamoorthi et al., 2005). The presence
of B. burgdorferi within ticks causes a marked increase in
the production of Salp15 by the I. scapularis salivary glands.
As B. burgdorferi migrate through the tick, the spirochetes
become coated with Salp15 via binding to OspC. Salp15-coated
B. burgdorferi are protected from antibody-mediated killing
(Ramamoorthi et al., 2005), and this increases the ability of
B. burgdorferi to infect mice. These properties make it an attrac-
tive target to influence B. burgdorferi infection.
Mice receiving Salp15 antiserum by passive transfer were
significantly protected from intradermal syringe challenge with
Salp15-coated B. burgdorferi or tick-transmitted spirochetes.
A plausible reason that Salp15 antibody provided partial immu-
nity against tick-borne B. burgdorferi is that there may be addi-
tional tick salivary proteins that interact with the spirochete in
the tick, thereby affording additional protection. Salp15 anti-
serum did not influence the ability of ticks to normally engorge
or the transmission of another I. scapularis-borne pathogen,
Anaplasma phagocytophilum, suggesting that this protection is
unique to Borrelia. This is consistent with the observation that
Salp15 specifically binds to Borrelia OspC, and this interaction& Microbe 6, 482–492, November 19, 2009 ª2009 Elsevier Inc. 489
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Salp15 Antiserum Prevents B. burgdorferi Infectionis critical for spirochete infection. Salp15 antiserum also
enhanced a traditional pathogen-based vaccine: in this case,
OspA. The OspA vaccine had 79% efficacy in phase III trials,
and vaccine failure was strongly associated with low titers of
OspA antibodies (Steere et al., 1998). Using a murine model,
we delineated the amount of an OspA-specific mAb required
to afford protection against tick-borne B. burgdorferi (de Silva
et al., 1999). Our data now show that Salp15 antiserum clearly
augments the protective capacity of the OspA mAb. In addition,
in active immunization studies, Salp15 elicited protection and
also increased the protective effect of OspA immunization
when both antigens were used together: these data suggest
that although Salp15 was first identified as an immunosuppres-
sive protein (Anguita et al., 2002), this may not limit its application
as a vaccine. Nevertheless, a mutant Salp15, which has a trun-
cated C terminus and does not have immunosuppressive prop-
erties, can also be used to generate Salp15 antibodies (data not
shown), eliminating any potential for immunosuppression. These
data show that antibodies directed toward an arthropod protein
that a pathogen uses to colonize themammalian host have a role
in immunity against a microbe, either individually or by comple-
menting a pathogen-specific vaccine.
We extended our studies by assessing another B. burgdorferi
antigen, OspC. OspC is induced on B. burgdorferi during tick
engorgement and plays an important role in the establishment
of mammalian infection. Xu et al. postulated that OspC is not
essential, because other lipoproteins can compensate for
OspC (Xu et al., 2008), based on needle-inoculation studies
that are quite different from the natural mode of B. burgdorferi
infection (transmitted by ticks, highly expressing OspC, and sur-
rounded by saliva). OspC antibodies have also been shown to be
partially protective against B. burgdorferi infection in various
animal models, but the heterogeneity of OspC among B. burg-
dorferi isolates makes it unlikely that a single OspC antigen
can serve as a vaccine (Earnhart et al., 2007; Probert et al.,
1997). We found that Salp15 antiserum increased the protective
capacity of OspC antiserum, demonstrating that the comple-
mentary effect of Salp15 is not limited to OspA.
Our data suggest that Salp15 antibodies interact with Salp15
on the surface of B. burgdorferi and thereby enhance clearance
by phagocytes. The mechanisms for the action of Salp15 anti-
bodies in vivomay involve opsonizing Salp15-boundB. burgdor-
feri to phagocytes and/or displacing Salp15 from the surface of
B. burgdorferi and unmasking the spirochetes for direct access
by the host immune system. The colocalization of Salp15 anti-
bodies on the surface of GFP-B. burgdorferi (Figure 5D)
suggests that opsonization by the Absmay be the primarymech-
anism for enhancing the elimination of the spirochete.
A vaccine needs to be as broadly protective as possible.
We then tested whether Salp15 antibodies could also have an
effect on other Borrelia species. Our data suggest that Salp15
not only binds to different strains of B. burgdorferi sensu stricto
but also binds to B. garinii and B. afzelii. This is consistent with
data showing that Salp15 homologs from tick I. ricinus can
also bind to B. burgdorferi sensu stricto, B. garinii, and B. afzelii
(Hovius et al., 2008b). Salp15 antibodies also enhanced the
phagocytosis of B. garinii and of B. afzelii in BMDMs. These
data suggest that Salp15 may have a role as a broad vaccine
candidate against different B. burgdorferi sensu lato species.490 Cell Host & Microbe 6, 482–492, November 19, 2009 ª2009 ElsThese data demonstrate a new approach for vaccine develop-
ment against arthropod-borne diseases—in this case, targeting
an I. scapularis protein that B. burgdorferi uses to enable infec-
tion of the vertebrate host. This strategy may prove effective
either by using the immune response to Salp15 exclusively or
as a complement to a vaccine based on a specific antigen on the
spirochete. Currently, vaccines against many life-threatening
arthropod-borne diseases, including dengue, malaria, and leish-
maniasis, among others, are not highly efficacious or are unavail-
able. Our data suggest that the extension of this paradigm,
developed with the Lyme disease agent, may be applicable to
other vector-borne infections of medical importance.
EXPERIMENTAL PROCEDURES
Spirochetes, Ticks, and Mice
A low-passage clonal isolate of B. burgdorferi N40 that is infectious in mice
was used throughout the study. B. burgdorferi B31 and GFP-B. burgdorferi
isolate 297, which constitutively express GFP (Eggers et al., 2002), were
used in the in vitro assays. B. garinii and B. afzelii were purchased from
ATCC and cultured in our lab.B. burgdorferiN40-infected I. scapularis nymphs
were obtained from The Connecticut Agricultural Experiment Station (New
Haven, CT). Female C3H/HeJ (C3H) mice, 4–6 weeks of age, were obtained
from the Jackson Laboratory.
Protection from Needle-Inoculated B. burgdorferi Infection
Recombinant Salp15 and rabbit Salp15 antiserum were made as described
(Anguita et al., 2002). Groups of ten mice were passively administered 200 ml
rabbit Salp15 antiserum, while control mice were administered 200 ml normal
rabbit serum. Before challenge, 107B. burgdorferi were first allowed to adhere
to 30 mg recombinant Salp15 for 1 hr at RT. B. burgdorferi were pelleted by
centrifugation, and free Salp15was removed bywashing the spirochetes twice
in PBS. Twenty-four hours after the passive immunization, mice were chal-
lengedwith an intradermal inoculation of 103 or 104 Salp15-coatedB. burgdor-
feri. Murine skin samples were collected at 1 week postinfection; murine
heart and joint samples were collected at 3 weeks postinfection. The murine
b-actin gene was used to normalize the amount of DNA in these samples,
and flaB was used to quantify the levels of spirochetes in the tissue samples
by Q-PCR.
Protection from Tick-Transmitted Infection
We previously showed that, in C3H mice, a minimum titer of 6.0 mg OspA IgG/
ml blood was required to protect mice from tick-transmitted B. burgdorferi
infection (de Silva et al., 1999). Groups of five mice were passively immunized
with normal rabbit serum (as control), a low dose of OspAmAb (4 mg/ml mouse
blood, little protection), a low dose of OspAmAb plus 100 ml Salp15 antiserum,
a high dose of OspA mAb (20 mg/ml mouse blood, full protection), or 200 ml
Salp15 antiserum, respectively. Twenty-four hours after immunization, ten
B. burgdorferi-infected nymphal ticks were placed on each mouse. The path-
ogen burdens in the localized skin specimen at days 3 and 7 after tick repletion
and in the murine skin, heart, and joints at 3 weeks postinfection were deter-
mined by measuring flaB copies using Q-PCR.
For A. phagocytophilum infection, 24 hr after immunization, three A. phago-
cytophilum-infected nymphs were placed on each mouse. At days 3, 5, 7, and
12, mice were bled, and the Anaplasma burden in murine blood was deter-
mined by measuring Anaplasma 16srRNA gene copies using Q-PCR.
In the OspC studies, OspC rabbit antiserum was generated by immunizing
a rabbit with recombinant OspC protein in Freund’s adjuvant. Groups of
five mice were passively immunized with normal rabbit serum (as control),
a low dose of OspC Ab (20 mg/mouse, a low degree of protection), a low
dose of OspC Ab plus 100 ml Salp15 antiserum, a high dose of OspC Ab
(100 mg/mouse, a higher degree of protection), a high dose of OspC Ab plus
100 ml Salp15 antiserum, or 200 ml Salp15 antiserum, respectively. The tick
challenge and pathogen burden analysis were performed using the same
methods described above.evier Inc.
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In active immunization study, a group of five mice was immunized by subcuta-
neously injecting 10 mg purified recombinant Salp15, Salp25D (a control saliva
protein) suspended in complete Freund’s adjuvant (CFA), or adjuvant alone
(mock control). Recombinant Salp15 and Salp25D were made as described
previously (Anguita et al., 2002; Narasimhan et al., 2007b). Mice were boosted
with 5 mg antigen suspended in incomplete Freund’s adjuvant every 2 weeks.
Additionally, at 1 day before tick challenge, groups of five Salp15-immunized
mice and five mock mice received a low dose of OspA mAb (4 mg/ml mouse
blood.) The tick challenge and pathogen burden analysis were performed
using the same methods described above.
To test whether the immunosuppressive properties of Salp15 influenced
antibody production against a prototypic pathogen-specific antigen (OspA),
mice were immunized with 10 mg OspA, OspA plus Salp15 (5 mg), and OspA
plus Salp25D (5 mg), together with CFA. Two weeks after immunization, mice
were bled, and the IgG titer of OspA was measured by ELISA. The tick chal-
lenge and pathogen burden analysis were performed using the samemethods
described above.
Q-PCR Analysis
All Q-PCR assays were performed with an iCycler (Bio-Rad Laboratories;
Hercules, CA) using high-fidelity Platinum Taq DNA Polymerase (Invitrogen),
gene-specific primers, and TaqMan probes with a program consisting of an
initial denaturing step of 3 min at 95C and 50 amplification cycles with 30 s
at 95C followed by 1 min at 60C. The forward and reverse primers and probe
used for Q-PCR analysis of flaB were 50-AGC TGA AGA GCT TGG AAT GC-30,
50-TTG GTT TGC TCC AAC ATG AA-30, and 50-TCC AAG ACG CTT GAG ACC
CTGAAA-30, respectively. The forward and reverse primers and probe used for
Q-PCRanalysis ofmouseb-actinwere50-AGAGGGAAATCGTGCGTGAC-30,
50-CAA TAGTGATGACCTGGCCGT-30, and 50-CACTGCCGCATCCTCTTC
CTC CC-30, respectively. The forward and reverse primers and probe used for
Q-PCR analysis of tick actin were 50-GAT CAT GTT CGA GAC CTT CA-30,
50-CGA TAC CCG TGG TAC GA-30, and 50-CCA TCC AGG CCG TGC TCT
C-30, respectively. The forward and reverse primers and probe used for
Q-PCR analysis of A. phagocytophilum 16srRNA gene were 50-TCG AAC
GGA TTA TTC TTT ATA GCT TG-30, 50-CCA TTT CTA GTG GCT ATC CCA
TAC TAC-30, and 50-TCA CCC GTC TGC CAC TAA CTA T-30, respectively.
Arthritis Analysis
Bilateral hind limb joints (knees and tibiotarsi) were processed and stained with
H&E byHSRL Laboratories (Mount Jackson, VA) or the Section of Comparative
Medicine, Yale School of Medicine (New Haven, CT). The knees and tibiotarsi
were scored for arthritis severity on a scale of 0 (negative) to 3 (severe) in
a blinded fashion as described previously (Barthold et al., 1997, 1992).
Microtiter Binding Assay
Chemically synthesized overlapping peptides of Salp15 (Anguita et al., 2002)
were purchased from the Yale University KECK facility. The different peptides
(0.5 mg) were coated overnight at 4C at the indicated concentrations in 0.1 M
sodium carbonate buffer (pH 9.5) in 96-well plates. The wells were blocked
with 10% FCS/PBS and incubated with recombinant OspC (0.5 mg), anti-
OspC Ab, and HRP-conjugated anti-rabbit IgG followed by microwell peroxi-
dase substrate (Kirkegaard & Perry Laboratories; Gaithersburg, MD). For
Salp15 peptide and Salp15 antibody binding, the wells (coated with individual
peptide) were probed with rabbit anti-Salp15 polyclonal antibodies followed
by HRP-conjugated anti-rabbit IgG and detected with peroxidase substrate.
In a competition assay, wells were coated with 0.5 mg Salp15 overnight,
probed with mixture of OspC and individual peptide, and detected by anti-
OspC Ab and HRP-conjugated anti-rabbit IgG.
In Vitro Phagocytosis Study
107 GFP-B. burgdorferi were first allowed to adhere to 30 mg recombinant
Salp15 for 1 hr at RT. B. burgdorferi were pelleted by centrifugation, and
free Salp15 was removed by washing the spirochetes twice in PBS. Murine
BMDMs were recovered from femurs and differentiated as described previ-
ously (Shin et al., 2008). BMDMs were subcultured in 12-well plates for
16 hr, and then Salp15-coated GFP spirochetes were added into the wells.
The cells were either treated with either 30 mg normal rabbit IgG or rabbitCell Hostanti-Salp15 IgG. The anti-Salp15 IgG and isotype IgG were purified from
sera by using Protein A/G agarose according to standard protocol. After incu-
bation for 4 hr, the cells were washed three times with PBS and fixed in 1%
paraformaldehyde. For confocal microscopy analysis, the cells were incu-
bated with TRITC-conjugated anti-rabbit IgG, and phagocytosis was detected
by the colocalization of GFP-spirochetes and TRITC staining. For flow cyto-
metric analysis, the cells were fixed in 1% PFA, scraped off the plate with
a policeman, and analyzed in a FACSCalibur (BD Biosciences).
For the phagocytosis assaywith different Borrelia species, 107B. burgdorferi
N40, B. garinii, or B. afzelii were coated with Salp15 and then incubated with
BMDMs and different antibodies for 4 hr. Cells were fixed and probed with
anti-OspA antibody and stained with Alexa 488-labeled anti-mouse IgG
(Invitrogen) and TRITC-labeled anti-rabbit IgG. Cells were then examined by
confocal microscope.
Salp15 Overlay Assay
To test whether Salp15 is also able to bind to OspC from other Borrelia
species, an overlay assay was performed as described (Ramamoorthi et al.,
2005). Extract from different B. burgdorferi sensu lato species were loaded
on the SDS-PAGE gel and transferred to a PVDF membrane. The membrane
was overlaid with recombinant Salp15 (with a V5 tag). After three washes by
PBST, the membrane was probed by HRP-conjugated anti-V5 antibody, and
the signal was analyzed by enhanced chemiluminescence (ECL) method.
Then the membrane was stripped and reprobed with OspC Ab followed by
HRP-conjugated anti-rabbit IgG and analyzed by ECL.
Statistical Analysis
The significance of the difference between the mean values of the groups was
evaluated using the Student’s t test with StatView software (SAS Institute;
Cary, NC).
SUPPLEMENTAL DATA
Supplemental Data include two figures and can be found online at http://www.
cell.com/cell-host-microbe/supplemental/S1931-3128(09)00348-5.
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